Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives
Emergent BioSolutions (NYSE: EBS) commends the U.S. House of Representatives for implementing over-the-counter (OTC) naloxone availability at all AED locations in its buildings. The initiative, led by Representative Buddy Carter (R-GA), aims to provide immediate access to life-saving treatment for potential opioid overdoses.
The company highlights that its NARCAN® Nasal Spray, the first OTC opioid overdose reversal treatment, has contributed to reducing overdose deaths according to CDC data. Since 2016, over 85 million doses have been distributed across the U.S. and Canada. As the leading U.S. supplier of nasal naloxone, Emergent offers multiple products including NARCAN® 4mg, KLOXXADO® 8mg, and various convenience kits.
Emergent BioSolutions (NYSE: EBS) elogia la Camera dei Rappresentanti degli Stati Uniti per aver reso disponibile il naloxone da banco (OTC) in tutte le postazioni AED presenti negli edifici governativi. L'iniziativa, guidata dal rappresentante Buddy Carter (R-GA), mira a garantire un accesso immediato a un trattamento salvavita in caso di possibili overdose da oppioidi.
L'azienda sottolinea che il suo NARCAN® Nasal Spray, il primo trattamento da banco per il sovradosaggio da oppioidi, ha contribuito a ridurre i decessi per overdose secondo i dati CDC. Dal 2016 sono state distribuite oltre 85 milioni di dosi negli Stati Uniti e in Canada. Come principale fornitore statunitense di naloxone nasale, Emergent offre diversi prodotti, tra cui NARCAN® 4mg, KLOXXADO® 8mg e vari kit di comodità.
Emergent BioSolutions (NYSE: EBS) felicita a la Cámara de Representantes de EE.UU. por implementar la disponibilidad de naloxona de venta libre (OTC) en todas las ubicaciones de DEA (desfibriladores externos automáticos) en sus edificios. La iniciativa, liderada por el representante Buddy Carter (R-GA), busca ofrecer acceso inmediato a un tratamiento que salva vidas ante posibles sobredosis de opioides.
La compañía destaca que su NARCAN® Nasal Spray, el primer tratamiento OTC para revertir sobredosis de opioides, ha ayudado a reducir las muertes por sobredosis según datos de los CDC. Desde 2016, se han distribuido más de 85 millones de dosis en EE.UU. y Canadá. Como principal proveedor estadounidense de naloxona nasal, Emergent ofrece múltiples productos, incluidos NARCAN® 4mg, KLOXXADO® 8mg y varios kits de conveniencia.
Emergent BioSolutions (NYSE: EBS)는 미국 하원에서 모든 AED 위치에 일반의약품(OTC) 나록손을 비치하도록 한 것을 환영합니다. 이 이니셔티브는 Buddy Carter 의원(R-GA)이 주도했으며, 잠재적인 오피오이드 과다복용에 즉각적으로 대응할 수 있는 생명을 구하는 치료 접근성을 제공하는 것을 목표로 합니다.
회사는 최초의 OTC 오피오이드 과다복용 해독 치료제인 NARCAN® 비강 스프레이가 CDC 데이터에 따르면 과다복용 사망 감소에 기여했다고 강조합니다. 2016년 이후 미국과 캐나다 전역에 8,500만 회 이상의 투여량이 배포되었습니다. 미국 내 비강 나록손 주요 공급업체로서 Emergent는 NARCAN® 4mg, KLOXXADO® 8mg 및 다양한 편의 키트를 포함한 여러 제품을 제공합니다.
Emergent BioSolutions (NYSE : EBS) félicite la Chambre des représentants des États-Unis pour avoir rendu le naloxone en vente libre (OTC) disponible à tous les emplacements AED dans ses bâtiments. L’initiative, menée par le représentant Buddy Carter (R-GA), vise à fournir un accès immédiat à un traitement salvateur en cas de surdose potentielle d’opioïdes.
L’entreprise souligne que son NARCAN® Spray nasal, le premier traitement OTC pour inverser une surdose d’opioïdes, a contribué à réduire les décès par surdose selon les données des CDC. Depuis 2016, plus de 85 millions de doses ont été distribuées aux États-Unis et au Canada. En tant que principal fournisseur américain de naloxone nasale, Emergent propose plusieurs produits, dont NARCAN® 4 mg, KLOXXADO® 8 mg et divers kits de commodité.
Emergent BioSolutions (NYSE: EBS) lobt das US-Repräsentantenhaus für die Einführung der Verfügbarkeit von Naloxon als rezeptfreies Medikament (OTC) an allen AED-Standorten in seinen Gebäuden. Die Initiative, angeführt von Abgeordnetem Buddy Carter (R-GA), zielt darauf ab, sofortigen Zugang zu lebensrettenden Behandlungen bei möglichen Opioid-Überdosierungen zu gewährleisten.
Das Unternehmen hebt hervor, dass sein NARCAN® Nasenspray, die erste OTC-Behandlung zur Umkehrung von Opioid-Überdosierungen, laut CDC-Daten zur Verringerung von Überdosierungs-Todesfällen beigetragen hat. Seit 2016 wurden über 85 Millionen Dosen in den USA und Kanada verteilt. Als führender US-Anbieter von nasalem Naloxon bietet Emergent mehrere Produkte an, darunter NARCAN® 4mg, KLOXXADO® 8mg und verschiedene Komfort-Kits.
- Over 85 million doses of NARCAN distributed in U.S. and Canada since 2016
- Position as leading U.S. supplier of nasal naloxone
- Expanded product range including NARCAN 4mg and KLOXXADO 8mg
- None.
GAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announces its recognition of the U.S. House of Representatives for adding over-the-counter (OTC) naloxone to every AED location in its buildings, providing direct access to first responders and anyone coming across an individual who may be experiencing an opioid overdose. This effort has been led by Representative Buddy Carter (R-GA), with his team and congressional constituents, who have kept this public health issue a priority.
Expanding access to potentially life-saving treatments is critical to saving more Americans and their families from an opioid overdose death. Emergent remains focused on saving lives through efforts to increase access, awareness and the availability of NARCAN® Nasal Spray 4 mg and KLOXXADO® Nasal Spray 8 mg. Emergent strives to engage with key stakeholders committed to reducing overdose deaths, as one death is one too many.
“The efforts of Representative Carter (R-GA) to make naloxone readily available in the U.S. House of Representatives are commendable, and we are pleased to recognize his work to help save a life during an opioid overdose emergency,” said Joe Papa, president and chief executive officer at Emergent. “We believe the over-the-counter availability of naloxone, including our product, NARCAN® Nasal Spray, has directly contributed to the reduction in overdose deaths reported by the U.S. Centers for Disease Control and Prevention. Measures like this reinforce the importance of having life-saving naloxone nearby as an opioid overdose can happen to anyone, anywhere and at any time.”
In 2023, Emergent launched NARCAN® Nasal Spray as the first OTC opioid overdose reversal treatment. With more than 85 million doses distributed in the U.S. and Canada since 2016, it is an important tool in helping save lives from opioid overdose, including those caused by fentanyl. Emergent is the leading U.S. supplier of nasal naloxone, and offers an expanded range of products to support public interest groups, workplaces/businesses, as well as patients, consumers and healthcare providers.
- NARCAN® (naloxone HCl) Nasal Spray 4 mg (two-dose carton)
- NARCAN® Nasal Spray Wall Unit Kit: includes wall unit cabinet with alarm, poster and wayfinder sign
- KLOXXADO® (naloxone HCl) Nasal Spray 8 mg (two-dose carton)
- Convenience Kits: includes medical grade components including: One hard case with internal pockets, one medical grade CPR mask, one pair of nitrile examination gloves
Visit NARCANDirect® or one of Emergent’s product sites, KLOXXADO.com and NARCAN.com to learn how to be prepared in an opioid overdose emergency with life-saving intranasal naloxone.
About NARCAN® Nasal Spray
NARCAN® Naloxone HCl Nasal Spray 4 mg is the first FDA-approved, over-the-counter (OTC) 4 mg naloxone product for the emergency treatment of opioid overdose. NARCAN® Nasal Spray is not a substitute for emergency medical care. Repeat dosing may be necessary. Use as directed.
Important Safety Information for KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
What is KLOXXADO® Nasal Spray?
- KLOXXADO® Nasal Spray is a prescription medicine used for the treatment of an opioid emergency such as an overdose or a possible opioid overdose in adults and children with signs of breathing problems and severe sleepiness or not being able to respond.
- KLOXXADO® Nasal Spray is to be given right away and does not take the place of emergency medical care.
- Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray, even if the person wakes up.
What is the most important information I should know about KLOXXADO® Nasal Spray?
Get emergency medical help right away after giving the first dose of KLOXXADO® Nasal Spray. The signs and symptoms of an opioid emergency can return after KLOXXADO® Nasal Spray is given. If this happens, give another dose after 2 to 3 minutes using a new KLOXXADO® Nasal Spray and watch the person closely until emergency help is received.
The medicine in KLOXXADO® Nasal Spray is safe to use in people who are not taking opioids. KLOXXADO® Nasal Spray is not intended for self-administration.
What should I tell my healthcare provider (pharmacist or prescriber) before using KLOXXADO® Nasal Spray?
Before using KLOXXADO® Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:
- have heart problems
- are pregnant or plan to become pregnant. Use of KLOXXADO® Nasal Spray may cause withdrawal symptoms in your unborn baby. Your unborn baby should be examined by a healthcare provider right away after you use KLOXXADO® Nasal Spray.
- are breastfeeding or plan to breastfeed. It is not known if KLOXXADO® Nasal Spray passes into your breast milk.
What are the possible serious side effects of KLOXXADO® Nasal Spray?
KLOXXADO® Nasal Spray may cause sudden opioid withdrawal symptoms including body aches, diarrhea, increased heart rate, fever, runny nose, sneezing, goose bumps, sweating, yawning, nausea or vomiting, nervousness, restlessness or irritability, shivering or trembling, stomach cramping, weakness, and increased blood pressure.
In infants under 4 weeks old who have been receiving opioids regularly, sudden opioid withdrawal may be life-threatening if not treated the right way. Signs and symptoms include seizures, crying more than usual, and increased reflexes.
Who should not use KLOXXADO® Nasal Spray?
Do not use KLOXXADO® Nasal Spray if you are allergic to naloxone hydrochloride or
any of the ingredients in KLOXXADO® Nasal Spray.
What are the most common side effects of KLOXXADO® nasal spray?
The most common side effects of KLOXXADO® Nasal Spray in adults include stomach-area (abdomen) pain, weakness, dizziness, headache, nose (nasal) discomfort, and a feeling like you are going to faint.
These are not all of the possible side effects of KLOXXADO® Nasal Spray. Please see full Prescribing Information, including Patient Information, which includes a more complete discussion of the risks associated with KLOXXADO® Nasal Spray. Always contact your healthcare provider (pharmacist or prescriber) if you have questions or experience any side effects.
You are encouraged to report negative side effects to the FDA at: 1-800-FDA-1088 or www.fda.gov/medwatch. You can also contact Hikma Specialty USA Inc. at: us.hikma@primevigilance.com or call 1-877-845-0689 or 1-800-962-8364.
Trademarks and logos are the property of their respective owners.
About Emergent BioSolutions
At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify.
Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com
Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com
FAQ
What is Emergent BioSolutions (EBS) role in addressing the opioid crisis?
How many doses of NARCAN has Emergent BioSolutions (EBS) distributed?
What products does Emergent BioSolutions (EBS) offer for opioid overdose treatment?
Where is NARCAN now available in the U.S. House of Representatives?
